Lucid-PSYCH
| Clinical data | |
|---|---|
| Other names | LUCID-PSYCH; Lucid-201 |
| Drug class | Undefined; Psychedelic; Hallucinogen |
Lucid-PSYCH, or LUCID-PSYCH, also known as Lucid-201, is a psychedelic hallucinogen which is under development for the treatment of major depressive disorder.[1][2][3][4][5] It is under development by Lucid Psycheceuticals.[1][2] Lucid-PSYCH's exact mechanism of action is undefined.[1][2] As of March 2023, it is in preclinical research and is progressing to phase 1 clinical trials.[1][2][6]
See also
References
- 1 2 3 4 "Lucid PSYCH - AdisInsight". adisinsight.springer.com.
- 1 2 3 4 "Delving into the Latest Updates on Lucid-201 with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
- ↑ "Mental health disorders | Neurodegenerative disorders | Toronto". Archived from the original on 2022-05-31.
- ↑ "Our Science". Archived from the original on 2023-06-05.
- ↑ https://www.sec.gov/Archives/edgar/data/1771885/000115752321001089/a52478064_ex991.htm "Lucid’s pipeline includes Lucid-201, a psychedelic drug candidate targeting mental health disorders, [...]"
- ↑ "Registration". ANZCTR. Retrieved 16 February 2025.
Categories:
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.